HSP90AA1 and plasma cell myeloma: Further, using 17-AAG (an HSP90 inhibitor) as the test secDrug, we added functional assays, next-generation RNA sequencing, CRISPR-based gene editing, and high-dimensional mass cytometry (CyTOF/cytometry time of flight) in primary bone marrow cells (PMCs; ex vivo model system) from myeloma patients to create a multi-pronged approach/pipeline to discover, validate and characterize novel drugs as potential secondary choices for circumventing resistance to primary drugs in myeloma and to generate better treatment outcomes.